Glioma extracellular vesicles for precision medicine: prognostic and theragnostic application

EV produced by tumour cells carry a diverse population of proteins, lipids, DNA, and RNA molecules throughout the body and appear to play an important role in the overall development of the disease state, according to growing data. Gliomas account for a sizable fraction of all primary brain tumours and the vast majority of brain malignancies. Glioblastoma multiforme (GBM) is a kind of grade IV glioma that has a very dismal prognosis despite advancements in diagnostic methods and therapeutic options. The authors discuss advances in understanding the function of extracellular vesicles (EVs), in overall glioma growth, as well as how recent research is uncovering the utility of EVs in glioma diagnostics, prognostic and therapeutics approaches

Xeno-free trans-differentiation of adipose tissue-derived mesenchymal stem cells into glial and neuronal cells.

Mesenchymal stem cells (MSCs) are undifferentiated cells that have the ability of self-renewal and trans-differentiation into other cell types. They hold out hope for finding a cure for many diseases. Nevertheless, there are still some obstacles that limit their clinical transplantation. One of these obstacles are the xenogeneic substances added in either proliferation or differentiation media with subsequent immunogenic and infectious transmission problems. In this study, we aimed to replace fetal bovine serum (FBS), the main nutrient source for MSC proliferation with xeno-free blood derivatives. We tested the effect of human activated pure platelet-rich plasma (P-PRP) and advanced platelet-rich fibrin (A-PRF) on the proliferation of human adipose derived-MSCs (AD-MSCs) at different concentrations. For the induction of MSC neural differentiation, we used human cerebrospinal fluid (CSF) at different concentrations in combination with P-PRP to effect xeno-free/species-specific neuronal/glial differentiation and we found that media with 10% CSF and 10% PRP promoted glial differentiation, while media with only 10% PRP induced a neuron-like phenotype

Modulation of enrofloxacin binding in OmpF by Mg2+ as revealed by the analysis of fast flickering single-porin current

One major determinant of the efficacy of antibiotics on Gram-negative bacteria is the passage through the outer membrane. During transport of the fluoroquinolone enrofloxacin through the trimeric outer membrane protein OmpF of Escherichia coli, the antibiotic interacts with two binding sites within the pore, thus partially blocking the ionic current. The modulation of one affinity site by Mg2+ reveals further details of binding sites and binding kinetics. At positive membrane potentials, the slow blocking events induced by enrofloxacin in Mg2+-free media are converted to flickery sojourns at the highest apparent current level (all three pores flickering). This indicates weaker binding in the presence of Mg2+. Analysis of the resulting amplitude histograms with beta distributions revealed the rate constants of blocking (k(OB)) and unblocking (k(BO)) in the range of 1,000 to 120,000 s(-1). As expected for a bimolecular reaction, k(OB) was proportional to blocker concentration and k(BO) independent of it. k(OB) was approximately three times lower for enrofloxacin coming from the cis side than from the trans side. The block was not complete, leading to a residual conductivity of the blocked state being similar to 25% of that of the open state. Interpretation of the results has led to the following model: fast flickering as caused by interaction of Mg2+ and enrofloxacin is related to the binding site at the trans side, whereas the cis site mediates slow blocking events which are also found without Mg2+. The difference in the accessibility of the binding sites also explains the dependency of k(OB) on the side of enrofloxacin addition and yields a means of determining the most plausible orientation of OmpF in the bilayer. The voltage dependence suggests that the dipole of the antibiotic has to be adequately oriented to facilitate binding

Environmental geochemistry of radioactive contamination.

This report attempts to describe the geochemical foundations of the behavior of radionuclides in the environment. The information is obtained and applied in three interacting spheres of inquiry and analysis: (1) experimental studies and theoretical calculations, (2) field studies of contaminated and natural analog sites and (3) model predictions of radionuclide behavior in remediation and waste disposal. Analyses of the risks from radioactive contamination require estimation of the rates of release and dispersion of the radionuclides through potential exposure pathways. These processes are controlled by solubility, speciation, sorption, and colloidal transport, which are strong functions of the compositions of the groundwater and geomedia as well as the atomic structure of the radionuclides. The chemistry of the fission products is relatively simple compared to the actinides. Because of their relatively short half-lives, fission products account for a large fraction of the radioactivity in nuclear waste for the first several hundred years but do not represent a long-term hazard in the environment. The chemistry of the longer-lived actinides is complex; however, some trends in their behavior can be described. Actinide elements of a given oxidation state have either similar or systematically varying chemical properties due to similarities in ionic size, coordination number, valence, and electron structure. In dilute aqueous systems at neutral to basic pH, the dominant actinide species are hydroxy- and carbonato-complexes, and the solubility-limiting solid phases are commonly oxides, hydroxides or carbonates. In general, actinide sorption will decrease in the presence of ligands that complex with the radionuclide; sorption of the (IV) species of actinides (Np, Pu, U) is generally greater than of the (V) species. The geochemistry of key radionuclides in three different environments is described in this report. These include: (1) low ionic strength reducing waters from crystalline rocks at nuclear waste research sites in Sweden; (2) oxic water from the J-13 well at Yucca Mountain, Nevada, the site of a proposed repository for high level nuclear waste (HLW) in tuffaceous rocks; and (3) reference brines associated with the Waste Isolation Pilot Plant (WIPP). The transport behaviors of radionuclides associated with the Chernobyl reactor accident and the Oklo Natural Reactor are described. These examples span wide temporal and spatial scales and include the rapid geochemical and physical processes important to nuclear reactor accidents or industrial discharges as well as the slower processes important to the geologic disposal of nuclear waste. Application of geochemical information to remediating or assessing the risk posed by radioactive contamination is the final subject of this report. After radioactive source terms have been removed, large volumes of soil and water with low but potentially hazardous levels of contamination may remain. For poorly-sorbing radionuclides, capture of contaminated water and removal of radionuclides may be possible using permeable reactive barriers and bioremediation. For strongly sorbing radionuclides, contaminant plumes will move very slowly. Through a combination of monitoring, regulations and modeling, it may be possible to have confidence that they will not be a hazard to current or future populations. Abstraction of the hydrogeochemical properties of real systems into simple models is required for probabilistic risk assessment. Simplifications in solubility and sorption models used in performance assessment calculations for the WIPP and the proposed HLW repository at Yucca Mountain are briefly described

Two open states and rate-limiting gating steps revealed by intracellular Na+ block of human KCNQ1 and KCNQ1/KCNE1 K+ channels

KCNQ1, the first member of a new K+ channel family, associates with the small KCNE1 subunit to form the slow cardiac delayed rectifier current, IKs. Mutations in both genes encoding these channels lead to cardiac arrhythmia. We studied the block by intracellular Na+ of human homomeric KCNQ1 (homomers) and heteromeric KCNQ1/KCNE1 (heteromers) expressed in CHO cells (Chinese hamster ovary cell line) using whole-cell patch recording.In the nominal absence of extracellular K+ and with 65 mm intracellular K+, the replacement of 65 mm intracellular N-methyl-d-glucamine (NMDG+) by 65 mm Na+ induced a decay of outward (K+) currents through homomers after maximal activation reminiscent of an inactivation process. The decay had a time constant in the hundreds of milliseconds range.The inactivation process of homomers was, however, not directly dependent on [Na+]i, as evidenced by unaltered biphasic deactivation at negative voltages.An instantaneous voltage-dependent Na+ block of homomers was revealed using tail current protocols with activating prepulses that saturated the gating processes of the channel. The instantaneous block was partially relieved at very large positive voltages (≥ 60 mV) and in 20 mm extracellular K+. The instantaneous block of homomers was much less pronounced if the tail currents were measured after short activating prepulses, demonstrating the presence of (at least) two open states: a first, relatively [Na+]i-insensitive and a subsequent [Na+]i-sensitive open state; the current decay reflects the transition between the two open states.Heteromers exhibited a very similar instantaneous block by Nai+ independently of the prepulse duration. Heteromers did not show a Nai+-induced current decay.Our results demonstrate the presence of two open states of KCNQ1 channels with different [Na+]i sensitivities. The rate-limiting step of homomeric KCNQ1 gating at positive voltages is the transition between these two open states. The rate-limiting step of the gating of KCNQ1/KCNE1 channels appears to be the entry into the first open state

Pandemic COVID-19 caused by SARS-CoV-2: genetic structure, vaccination, and therapeutic approaches

We give a summary of SARS-genetic CoV-2’s structure and evolution, as well as current attempts to develop efficient vaccine and treatment methods for SARS-CoV-2 infection, in this article. Most therapeutic strategies are based on repurposing of existing therapeutic agents used against various virus infections and focused mainly on inhibition of the virus replication cycle, enhancement of innate immunity, and alleviation of CRS caused by COVID-19. Currently, more than 100 clinical trials on COVID-19 aim to provide robust evidence on the efficacy of the currently available anti-SARS-CoV-2 antiviral substances, such as the nucleotide analogue remdesivir, the antimalarial drug chloroquine, and drugs directed against docking of SARS-CoV-2 to the membrane-associated angiotensin-converting enzyme 2 (ACE2) such as transmembrane protease serine 2 (TMPRSS2). The current vaccination campaign is ongoing worldwide using different types of vaccines such as Pfizer-BioNTech and Moderna, Johnson & Johnson, Oxford-AstraZeneca, Novavax, and others with efficacy ranging from 72–95%. In March 2021 Germany limited the use of the Oxford-AstraZeneca COVID-19 vaccine to people 60 years of age and older due to concerns that it may be causing blood clots. Further study and more data are needed to confirm the safety of different available vaccines

Common and Rare Genetic Variants Associated With Alzheimer's Disease

Alzheimer's disease (AD) is one of the most devastating disorders. Despite the continuing increase of its incidence among aging populations, no effective cure has been developed mainly due to difficulties in early diagnosis of the disease before damaging of the brain, and the failure to explore its complex underlying molecular mechanisms. Recent technological advances in genome-wide association studies (GWAS) and high throughput next generation whole genome, and exome sequencing had deciphered many of AD-related loci, and discovered single nucleotide polymorphisms (SNPs) that are associated with altered AD molecular pathways. Highlighting altered molecular pathways linked to AD pathogenesis is crucial to identify novel diagnostic and therapeutic AD targets.BRC, Q

Potential of Stem Cell-Based Therapy for Ischemic Stroke

Ischemic stroke is one of the major health problems worldwide. The only FDA approved anti-thrombotic drug for acute ischemic stroke is the tissue plasminogen activator. Several studies have been devoted to assessing the therapeutic potential of different types of stem cells such as neural stem cells (NSCs), mesenchymal stem cells, embryonic stem cells, and human induced pluripotent stem cell-derived NSCs as treatments for ischemic stroke. The results of these studies are intriguing but many of them have presented conflicting results. Additionally, the mechanism(s) by which engrafted stem/progenitor cells exert their actions are to a large extent unknown. In this review, we will provide a synopsis of different preclinical and clinical studies related to the use of stem cell-based stroke therapy, and explore possible beneficial/detrimental outcomes associated with the use of different types of stem cells. Due to limited/short time window implemented in most of the recorded clinical trials about the use of stem cells as potential therapeutic intervention for stroke, further clinical trials evaluating the efficacy of the intervention in a longer time window after cellular engraftments are still needed